Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging
|
Homo sapiens
|
-3.79
%
|
|
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate
|
Severe acute respiratory syndrome coronavirus 2
|
19.32
%
|
|
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate
|
Severe acute respiratory syndrome coronavirus 2
|
12.53
%
|
|
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging
|
Chlorocebus sabaeus
|
0.2
%
|
|
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging
|
Chlorocebus sabaeus
|
-0.06
%
|
|
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging
|
Chlorocebus sabaeus
|
0.2
%
|
|
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging
|
Chlorocebus sabaeus
|
-0.06
%
|
|
GPCRScan assay: inhibition of 5-HT1A
|
Homo sapiens
|
-22.74
%
|
|
GPCRScan assay: inhibition of 5-HT1B
|
Homo sapiens
|
-11.25
%
|
|
GPCRScan assay: inhibition of 5-HT1D
|
Homo sapiens
|
-24.02
%
|
|
GPCRScan assay: inhibition of 5-HT1E
|
Homo sapiens
|
10.97
%
|
|
GPCRScan assay: inhibition of 5-HT2A
|
Homo sapiens
|
6.25
%
|
|
GPCRScan assay: inhibition of 5-HT2B
|
Homo sapiens
|
-0.11
%
|
|
GPCRScan assay: inhibition of 5-HT2C
|
Homo sapiens
|
12.35
%
|
|
GPCRScan assay: inhibition of 5-HT3
|
Homo sapiens
|
0.08
%
|
|
GPCRScan assay: inhibition of 5-HT5A
|
Homo sapiens
|
-8.97
%
|
|
GPCRScan assay: inhibition of 5-HT6
|
Homo sapiens
|
-6.47
%
|
|
GPCRScan assay: inhibition of 5-HT7A
|
Homo sapiens
|
-9.26
%
|
|
GPCRScan assay: inhibition of D1
|
Homo sapiens
|
-26.64
%
|
|
GPCRScan assay: inhibition of D2
|
Homo sapiens
|
-23.45
%
|
|
GPCRScan assay: inhibition of D3
|
Homo sapiens
|
32.96
%
|
|
GPCRScan assay: inhibition of D4
|
Homo sapiens
|
8.76
%
|
|
GPCRScan assay: inhibition of D5
|
Homo sapiens
|
-2.51
%
|
|
GPCRScan assay: inhibition of SERT
|
Homo sapiens
|
-6.83
%
|
|
GPCRScan assay: inhibition of NET
|
Homo sapiens
|
11.01
%
|
|
GPCRScan assay: inhibition of DAT
|
Homo sapiens
|
-14.46
%
|
|
GPCRScan assay: inhibition of MOR
|
Homo sapiens
|
1.07
%
|
|
GPCRScan assay: inhibition of DOR
|
Homo sapiens
|
5.07
%
|
|
GPCRScan assay: inhibition of KOR
|
Homo sapiens
|
16.41
%
|
|
GPCRScan assay: inhibition of GABAA
|
Rattus
|
-1.97
%
|
|
GPCRScan assay: inhibition of H1
|
Homo sapiens
|
-11.53
%
|
|
GPCRScan assay: inhibition of H2
|
Homo sapiens
|
3.0
%
|
|
GPCRScan assay: inhibition of H3
|
Homo sapiens
|
-15.34
%
|
|
GPCRScan assay: inhibition of H4
|
Homo sapiens
|
-17.71
%
|
|
GPCRScan assay: inhibition of Alpha1A
|
Homo sapiens
|
2.52
%
|
|
GPCRScan assay: inhibition of Alpha1B
|
Homo sapiens
|
-11.36
%
|
|
GPCRScan assay: inhibition of Alpha2A
|
Homo sapiens
|
21.8
%
|
|
GPCRScan assay: inhibition of Alpha2B
|
Homo sapiens
|
9.24
%
|
|
GPCRScan assay: inhibition of Alpha2C
|
Homo sapiens
|
9.72
%
|
|
GPCRScan assay: inhibition of Beta1
|
Homo sapiens
|
-12.18
%
|
|
GPCRScan assay: inhibition of Beta2
|
Homo sapiens
|
-17.45
%
|
|
GPCRScan assay: inhibition of M1
|
Homo sapiens
|
-0.03
%
|
|
GPCRScan assay: inhibition of M2
|
Homo sapiens
|
16.71
%
|
|
GPCRScan assay: inhibition of M3
|
Homo sapiens
|
19.22
%
|
|
GPCRScan assay: inhibition of M4
|
Homo sapiens
|
-18.57
%
|
|
GPCRScan assay: inhibition of M5
|
Homo sapiens
|
-7.44
%
|
|
GPCRScan assay: inhibition of Beta3
|
Homo sapiens
|
-19.86
%
|
|
GPCRScan assay: inhibition of GABAA/BZP
|
Rattus
|
18.7
%
|
|
GPCRScan assay: inhibition of GABA/PBR
|
Rattus
|
-30.46
%
|
|
GPCRScan assay: inhibition of Alpha1D
|
Homo sapiens
|
-3.76
%
|
|
GPCRScan assay: inhibition of Sigma 2
|
Homo sapiens
|
-1.29
%
|
|
GPCRScan assay: inhibition of Sigma 1
|
Homo sapiens
|
21.07
%
|
|
Inhibition of binding to PTGER2
|
Homo sapiens
|
5.0
nM
|
|
Binding assay (PTGFR)
|
Homo sapiens
|
10.0
µM
|
|
Binding assay (PTGIR)
|
Homo sapiens
|
10.0
µM
|
|
Binding assay (TBXA2R)
|
Homo sapiens
|
10.0
µM
|
|
Binding assay (LTB4R )
|
Homo sapiens
|
4.8
µM
|
|
5-HT transporter (h) CEREP ligand profiling
|
Homo sapiens
|
-8.0
%
|
|
5-HT1A (h) CEREP ligand profiling
|
Homo sapiens
|
6.0
%
|
|
5-HT1B CEREP ligand profiling
|
Homo sapiens
|
-7.0
%
|
|
5-HT1D CEREP ligand profiling
|
None
|
-10.0
%
|
|
5-HT2A (h) CEREP ligand profiling
|
None
|
0.0
%
|
|
5-HT2A (h) (agonist site) CEREP ligand profiling
|
Homo sapiens
|
-15.0
%
|
|
5-HT2B (h) (agonist site/DOI) CEREP ligand profiling
|
Homo sapiens
|
13.0
%
|
|
5-HT2C (h) CEREP ligand profiling
|
Homo sapiens
|
8.0
%
|
|
5-HT2C (h) (agonist site) CEREP ligand profiling
|
Homo sapiens
|
-6.0
%
|
|
5-HT3 (h) CEREP ligand profiling
|
Homo sapiens
|
-6.0
%
|
|
5-HT4e (h) CEREP ligand profiling
|
Homo sapiens
|
-14.0
%
|
|
5-HT6 (h) CEREP ligand profiling
|
Homo sapiens
|
0.0
%
|
|
5-HT7 (h) CEREP ligand profiling
|
Homo sapiens
|
-2.0
%
|
|
A1 (h) CEREP ligand profiling
|
Homo sapiens
|
-2.0
%
|
|
A2A (h) CEREP ligand profiling
|
Homo sapiens
|
-9.0
%
|
|
A3 (h) CEREP ligand profiling
|
Homo sapiens
|
-10.0
%
|
|
Abl kinase (h) CEREP ligand profiling
|
Homo sapiens
|
9.0
%
|
|
ACE (h) CEREP ligand profiling
|
Homo sapiens
|
14.0
%
|
|
Acetylcholinesterase (h) CEREP ligand profiling
|
Homo sapiens
|
45.0
%
|
|
alpha 1 (non- selective) CEREP ligand profiling
|
None
|
9.0
%
|
|
alpha 2A (h) CEREP ligand profiling
|
Homo sapiens
|
26.0
%
|
|
alpha 2B (h) CEREP ligand profiling
|
Homo sapiens
|
1.0
%
|
|
alpha 2C (h) CEREP ligand profiling
|
Homo sapiens
|
4.0
%
|
|
AMPA CEREP ligand profiling
|
None
|
-13.0
%
|
|
Androgen (h) (AR) CEREP ligand profiling
|
Homo sapiens
|
0.0
%
|
|
AT1 (h) CEREP ligand profiling
|
Homo sapiens
|
1.0
%
|
|
ATPase (Na+/K+) CEREP ligand profiling
|
Homo sapiens
|
5.0
%
|
|
beta 1 (h) CEREP ligand profiling
|
Homo sapiens
|
9.0
%
|
|
beta 2 (h) CEREP ligand profiling
|
Homo sapiens
|
-4.0
%
|
|
beta 3 (h) CEREP ligand profiling
|
Homo sapiens
|
3.0
%
|
|
Ca2+ channel (L, DHP site) CEREP ligand profiling
|
Homo sapiens
|
-3.0
%
|
|
Ca2+ channel (L, diltiazem site) CEREP ligand profiling
|
Homo sapiens
|
6.0
%
|
|
Ca2+ channel (L, verapamil site) CEREP ligand profiling
|
Homo sapiens
|
-5.0
%
|
|
Ca2+ channel (N) CEREP ligand profiling
|
Homo sapiens
|
-7.0
%
|
|
CaMK2alpha (h) CEREP ligand profiling
|
Homo sapiens
|
5.0
%
|
|
Carbonic anhydrase II (h) CEREP ligand profiling
|
Homo sapiens
|
9.0
%
|
|
Caspase-3 (h) CEREP ligand profiling
|
Homo sapiens
|
0.0
%
|
|
CB1 (h) CEREP ligand profiling
|
Homo sapiens
|
0.0
%
|
|
CB2 (h) CEREP ligand profiling
|
Homo sapiens
|
0.0
%
|
|
CCKA (h) (CCK1) CEREP ligand profiling
|
Homo sapiens
|
29.0
%
|
|
CCKB (h) (CCK2) CEREP ligand profiling
|
Homo sapiens
|
-8.0
%
|
|
Choline transporter (h) (CHT1) CEREP ligand profiling
|
Homo sapiens
|
4.0
%
|
|
Cl- channel CEREP ligand profiling
|
None
|
19.0
%
|
|
COX1 (h) CEREP ligand profiling
|
Homo sapiens
|
-25.0
%
|
|
COX2 (h) CEREP ligand profiling
|
Homo sapiens
|
2.0
%
|
|
CXCR4 (h) CEREP ligand profiling
|
Homo sapiens
|
4.0
%
|
|
CYP2C19 inhibition CEREP ligand profiling
|
None
|
5.0
%
|
|
CYP2C9 inhibition CEREP ligand profiling
|
None
|
41.0
%
|
|
CYP2D6 inhibition CEREP ligand profiling
|
None
|
18.0
%
|
|
CYP3A4 inhibition CEREP ligand profiling
|
None
|
17.0
%
|
|
D1 (h) CEREP ligand profiling
|
Homo sapiens
|
5.0
%
|
|
D2S (h) CEREP ligand profiling
|
Homo sapiens
|
-2.0
%
|
|
D2S (h) (agonist site) CEREP ligand profiling
|
Homo sapiens
|
-6.0
%
|
|
D3 (h) CEREP ligand profiling
|
Homo sapiens
|
1.0
%
|
|
D4.4 (h) CEREP ligand profiling
|
Homo sapiens
|
-8.0
%
|
|
DA transporter (h) CEREP ligand profiling
|
Homo sapiens
|
11.0
%
|
|
delta 2 (h) (DOP) CEREP ligand profiling
|
Homo sapiens
|
0.0
%
|
|
ETA (h) CEREP ligand profiling
|
Homo sapiens
|
3.0
%
|
|
ETB (h) CEREP ligand profiling
|
Homo sapiens
|
-1.0
%
|
|
FLT-1 kinase (h) (VEGFR1) CEREP ligand profiling
|
Homo sapiens
|
9.0
%
|
|
GABAA BZD (central) CEREP ligand profiling
|
None
|
10.0
%
|
|
GABA transporter CEREP ligand profiling
|
None
|
14.0
%
|
|
GABAA CEREP ligand profiling
|
None
|
16.0
%
|
|
GABAB (1b) (h) CEREP ligand profiling
|
Homo sapiens
|
-21.0
%
|
|
Ghrelin (h) (GHS) CEREP ligand profiling
|
Homo sapiens
|
-6.0
%
|
|
GR (h) CEREP ligand profiling
|
Homo sapiens
|
-1.0
%
|
|
Glycine (strychnine-insensitive) CEREP ligand profiling
|
None
|
11.0
%
|
|
H1 (h) CEREP ligand profiling
|
Homo sapiens
|
0.0
%
|
|
H2 (h) CEREP ligand profiling
|
Homo sapiens
|
3.0
%
|
|
H3 (h) CEREP ligand profiling
|
Homo sapiens
|
10.0
%
|
|
H4 (h) CEREP ligand profiling
|
Homo sapiens
|
-4.0
%
|
|
I1 CEREP ligand profiling
|
None
|
-14.0
%
|
|
Kainate CEREP ligand profiling
|
None
|
-15.0
%
|
|
kappa (KOP) CEREP ligand profiling
|
Homo sapiens
|
46.0
%
|
|
LTB4 (h) (BLT1) CEREP ligand profiling
|
Homo sapiens
|
51.0
%
|
|
LTD4 (h) (CysLT1) CEREP ligand profiling
|
Homo sapiens
|
2.0
%
|
|
Lyn kinase (h) CEREP ligand profiling
|
Homo sapiens
|
2.0
%
|
|
M1 (h) CEREP ligand profiling
|
Homo sapiens
|
9.0
%
|
|
M2 (h) CEREP ligand profiling
|
Homo sapiens
|
1.0
%
|
|
M3 (h) CEREP ligand profiling
|
Homo sapiens
|
1.0
%
|
|
M4 (h) CEREP ligand profiling
|
Homo sapiens
|
0.0
%
|
|
M5 (h) CEREP ligand profiling
|
Homo sapiens
|
1.0
%
|
|
MAO-A CEREP ligand profiling
|
None
|
3.0
%
|
|
MC1 CEREP ligand profiling
|
None
|
6.0
%
|
|
MC3 (h) CEREP ligand profiling
|
Homo sapiens
|
-11.0
%
|
|
MC4 (h) CEREP ligand profiling
|
Homo sapiens
|
8.0
%
|
|
MCH1 (h) CEREP ligand profiling
|
Homo sapiens
|
-13.0
%
|
|
ML1 CEREP ligand profiling
|
None
|
-3.0
%
|
|
ML2 (MT3) CEREP ligand profiling
|
None
|
93.0
%
|
|
ML2 (MT3) CEREP ligand profiling
|
None
|
530.0
nM
|
|
ML2 (MT3) CEREP ligand profiling
|
None
|
520.0
nM
|
|
MMP-9 (h) CEREP ligand profiling
|
Homo sapiens
|
10.0
%
|
|
Motilin (h) CEREP ligand profiling
|
Homo sapiens
|
-5.0
%
|
|
mu (h) (MOP) (agonist site) CEREP ligand profiling
|
Homo sapiens
|
-7.0
%
|
|
N (muscle-type) (h) CEREP ligand profiling
|
Homo sapiens
|
-10.0
%
|
|
N (neuronal) (alpha -BGTX-insensitive) (alpha 4 beta 2) CEREP ligand profiling
|
None
|
-10.0
%
|
|
Na+ channel (site 2) CEREP ligand profiling
|
None
|
9.0
%
|
|
NE transporter (h) CEREP ligand profiling
|
Homo sapiens
|
-2.0
%
|
|
NK1 (h) CEREP ligand profiling
|
Homo sapiens
|
3.0
%
|
|
NK2 (h) CEREP ligand profiling
|
Homo sapiens
|
0.0
%
|
|
NMDA CEREP ligand profiling
|
None
|
1.0
%
|
|
p38 alpha kinase (h) CEREP ligand profiling
|
Homo sapiens
|
-1.0
%
|
|
PCP CEREP ligand profiling
|
None
|
-6.0
%
|
|
PDE11 (h) CEREP ligand profiling
|
Homo sapiens
|
14.0
%
|
|
PDE2 (h) CEREP ligand profiling
|
Homo sapiens
|
5.0
%
|
|
PDE3 (h) CEREP ligand profiling
|
Homo sapiens
|
78.0
%
|
|
PDE4 (h) CEREP ligand profiling
|
Homo sapiens
|
8.0
%
|
|
PDE5 (h) CEREP ligand profiling
|
Homo sapiens
|
6.0
%
|
|
PDE6 CEREP ligand profiling
|
None
|
3.0
%
|
|
PPAR gamma (h) CEREP ligand profiling
|
Homo sapiens
|
14.0
%
|
|
Rolipram CEREP ligand profiling
|
None
|
3.0
%
|
|
sigma (non-selective) CEREP ligand profiling
|
None
|
0.0
%
|
|
SK+Ca channel CEREP ligand profiling
|
None
|
-1.0
%
|
|
sst4 (h) CEREP ligand profiling
|
Homo sapiens
|
0.0
%
|
|
TH CEREP ligand profiling
|
None
|
-10.0
%
|
|
TNF-alpha (h) CEREP ligand profiling
|
Homo sapiens
|
-1.0
%
|
|
TXA2/P GH2 (h)(TP) CEREP ligand profiling
|
Homo sapiens
|
0.0
%
|
|
UT1 (h) CEREP ligand profiling
|
Homo sapiens
|
14.0
%
|
|
V1a (h) CEREP ligand profiling
|
Homo sapiens
|
-3.0
%
|
|
V2 (h) CEREP ligand profiling
|
Homo sapiens
|
-1.0
%
|
|
VIP1 (h) (VPAC1) CEREP ligand profiling
|
Homo sapiens
|
-13.0
%
|
|
Y1 (h) CEREP ligand profiling
|
Homo sapiens
|
1.0
%
|
|
ZAP70 kinase (h) CEREP ligand profiling
|
Homo sapiens
|
9.0
%
|
|